University Hospital of Wales, Cardiff, UK.
Interv Neuroradiol. 2021 Dec;27(6):805-814. doi: 10.1177/15910199211011887. Epub 2021 Apr 22.
BACKGROUND/PURPOSE: pCONUS 2 and pCONUS 2-HPC are novel neck-bridging devices designed to support endovascular coil occlusion of wide-necked intracranial bifurcation aneurysms. This study summarises periprocedural outcomes, 6-month, and early 2-year follow-up results following its introduction in an interventional neuroradiology centre.
MATERIALS/METHODS: This prospective, single-arm study assessed 20 aneurysms treated over a 40 month time period from time of procedure to 2 years post-procedure. Data collected included patient demographics, aneurysm features, and intraprocedural, 6-month, and 2-year post-procedural complications and angiographic features.
The mean age of the cohort was 59+-SD 7.7 years. 16 unruptured aneurysms were treated (pCONUS 2 13/16, pCONUS 2-HPC 3/16) and 4 ruptured aneurysms were treated with pCONUS 2-HPC. Unruptured cases received dual antiplatelet therapy pre- and post-procedure while ruptured cases received single antiplatelet therapy. 9/20 aneurysms were located at the MCA bifurcation and 7/20 at the basilar tip. The remaining 4 aneurysms were at various bifurcations in the anterior circulation. 11/20 were small (<10mm) and 9/20 were large (10-25mm). There was one periprocedural complication: a retroperitoneal bleed. There were no post-procedural intracranial complications or at 6-months follow-up. At 6 months, satisfactory occlusion was achieved in 94% of cases (15/16). There was one delayed death at 2-year follow-up from an unrelated cause.
pCONUS 2 and pCONUS 2-HPC have excellent short and medium-term safety profiles and clinical outcomes with no procedure-related mortality or morbidity and good occlusion rates at 6-month follow-up. The use of pCONUS 2-HPC with single antiplatelet therapy is feasible and did not cause any complications.
背景/目的:pCONUS 2 和 pCONUS 2-HPC 是两种新型的颈部桥接装置,旨在支持血管内线圈闭塞宽颈颅内分叉动脉瘤。本研究总结了该装置在介入神经放射学中心引入后的围手术期结果、6 个月和早期 2 年随访结果。
材料/方法:这是一项前瞻性、单臂研究,评估了 20 例动脉瘤,从手术开始到 2 年后的时间内共 40 个月。收集的数据包括患者人口统计学特征、动脉瘤特征、术中、6 个月和 2 年的并发症和血管造影特征。
队列的平均年龄为 59+/-7.7 岁。16 例未破裂的动脉瘤接受了治疗(pCONUS 2 13/16,pCONUS 2-HPC 3/16),4 例破裂的动脉瘤接受了 pCONUS 2-HPC 治疗。未破裂的病例在术前和术后接受双联抗血小板治疗,而破裂的病例则接受单联抗血小板治疗。20 例动脉瘤中有 9 例位于 MCA 分叉处,7 例位于基底动脉尖。其余 4 例动脉瘤位于前循环的不同分叉处。20 例动脉瘤中有 11 例较小(<10mm),9 例较大(10-25mm)。有 1 例围手术期并发症:腹膜后出血。术后无颅内并发症或 6 个月随访时无并发症。6 个月时,94%(15/16)的病例达到了满意的闭塞。在 2 年随访时有 1 例因其他原因死亡。
pCONUS 2 和 pCONUS 2-HPC 具有极好的短期和中期安全性和临床结果,无手术相关死亡率或发病率,6 个月随访时闭塞率良好。使用 pCONUS 2-HPC 联合单联抗血小板治疗是可行的,不会引起任何并发症。